[Which biological matrix for cannabis testing?].
Identifieur interne : 000295 ( PubMed/Curation ); précédent : 000294; suivant : 000296[Which biological matrix for cannabis testing?].
Auteurs : J-P Goullé [France] ; C. LacroixSource :
- Annales pharmaceutiques francaises [ 0003-4509 ] ; 2006.
English descriptors
- KwdEn :
- MESH :
- chemical , analysis : Cannabinoids, Dronabinol.
- chemical , pharmacokinetics : Cannabinoids, Dronabinol.
- adverse effects : Cannabis.
- chemistry : Cannabis.
- Automobile Driving, Humans, Tissue Distribution.
Abstract
Decisive analytical progress for biological cannabis testing has been achieved over the past ten years. These major contributions allow to accurately identify and quantify in detail the substances present in the body following cannabinoid exposure. Fast and reliable onsite urine testing is used to implement the French law on narcotic drugs and its relationship to motorway safety. A positive test result will indicate a very recent exposure which is detectable up to five days following intake. Then a clinical examination and blood collection are performed by a physician, with a subsequent blood tetrahydrocannabinol (THC) analysis by authorized professionals registered at the judicial court of appeal. A result higher than the cut-off value is associated with a very recent cannabis exposure. Blood, urine, saliva and sweat cannabis determination are assessed according to the most recent pharmacokinetic and analytical data.
PubMed: 16710116
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000295
Links to Exploration step
pubmed:16710116Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Which biological matrix for cannabis testing?].</title>
<author><name sortKey="Goulle, J P" sort="Goulle, J P" uniqKey="Goulle J" first="J-P" last="Goullé">J-P Goullé</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe hospitalier du Havre, BP 24, F 76083 Le Havre Cedex. jgoulle@ch-havre.fr</nlm:affiliation>
<country wicri:rule="url">France</country>
</affiliation>
</author>
<author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16710116</idno>
<idno type="pmid">16710116</idno>
<idno type="wicri:Area/PubMed/Corpus">000295</idno>
<idno type="wicri:Area/PubMed/Curation">000295</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Which biological matrix for cannabis testing?].</title>
<author><name sortKey="Goulle, J P" sort="Goulle, J P" uniqKey="Goulle J" first="J-P" last="Goullé">J-P Goullé</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe hospitalier du Havre, BP 24, F 76083 Le Havre Cedex. jgoulle@ch-havre.fr</nlm:affiliation>
<country wicri:rule="url">France</country>
</affiliation>
</author>
<author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
</author>
</analytic>
<series><title level="j">Annales pharmaceutiques francaises</title>
<idno type="ISSN">0003-4509</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Automobile Driving</term>
<term>Cannabinoids (analysis)</term>
<term>Cannabinoids (pharmacokinetics)</term>
<term>Cannabis (adverse effects)</term>
<term>Cannabis (chemistry)</term>
<term>Dronabinol (analysis)</term>
<term>Dronabinol (pharmacokinetics)</term>
<term>Humans</term>
<term>Tissue Distribution</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Cannabinoids</term>
<term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Cannabinoids</term>
<term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Cannabis</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Cannabis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Automobile Driving</term>
<term>Humans</term>
<term>Tissue Distribution</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Decisive analytical progress for biological cannabis testing has been achieved over the past ten years. These major contributions allow to accurately identify and quantify in detail the substances present in the body following cannabinoid exposure. Fast and reliable onsite urine testing is used to implement the French law on narcotic drugs and its relationship to motorway safety. A positive test result will indicate a very recent exposure which is detectable up to five days following intake. Then a clinical examination and blood collection are performed by a physician, with a subsequent blood tetrahydrocannabinol (THC) analysis by authorized professionals registered at the judicial court of appeal. A result higher than the cut-off value is associated with a very recent cannabis exposure. Blood, urine, saliva and sweat cannabis determination are assessed according to the most recent pharmacokinetic and analytical data.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16710116</PMID>
<DateCreated><Year>2006</Year>
<Month>5</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted><Year>2006</Year>
<Month>08</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-4509</ISSN>
<JournalIssue CitedMedium="Print"><Volume>64</Volume>
<Issue>3</Issue>
<PubDate><Year>2006</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Annales pharmaceutiques francaises</Title>
<ISOAbbreviation>Ann Pharm Fr</ISOAbbreviation>
</Journal>
<ArticleTitle>[Which biological matrix for cannabis testing?].</ArticleTitle>
<Pagination><MedlinePgn>181-91</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Decisive analytical progress for biological cannabis testing has been achieved over the past ten years. These major contributions allow to accurately identify and quantify in detail the substances present in the body following cannabinoid exposure. Fast and reliable onsite urine testing is used to implement the French law on narcotic drugs and its relationship to motorway safety. A positive test result will indicate a very recent exposure which is detectable up to five days following intake. Then a clinical examination and blood collection are performed by a physician, with a subsequent blood tetrahydrocannabinol (THC) analysis by authorized professionals registered at the judicial court of appeal. A result higher than the cut-off value is associated with a very recent cannabis exposure. Blood, urine, saliva and sweat cannabis determination are assessed according to the most recent pharmacokinetic and analytical data.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goullé</LastName>
<ForeName>J-P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo><Affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe hospitalier du Havre, BP 24, F 76083 Le Havre Cedex. jgoulle@ch-havre.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lacroix</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>FRE</Language>
<PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Mise en évidence des cannabinoïdes: quel milieu biologique?</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Ann Pharm Fr</MedlineTA>
<NlmUniqueID>2985176R</NlmUniqueID>
<ISSNLinking>0003-4509</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002186">Cannabinoids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7J8897W37S</RegistryNumber>
<NameOfSubstance UI="D013759">Dronabinol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D001334" MajorTopicYN="Y">Automobile Driving</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002186" MajorTopicYN="N">Cannabinoids</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002188" MajorTopicYN="N">Cannabis</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013759" MajorTopicYN="N">Dronabinol</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>42</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>8</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16710116</ArticleId>
<ArticleId IdType="pii">MDOI-APF-05-2006-64-3-0003-4509-101019-200601332</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000295 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000295 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/France |area= LeHavreV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:16710116 |texte= [Which biological matrix for cannabis testing?]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16710116" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LeHavreV1
This area was generated with Dilib version V0.6.25. |